Cambrex (CBM) Stock Rating Lowered by Zacks Investment Research
Cambrex (NYSE:CBM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “
Several other research analysts have also recently commented on the company. William Blair initiated coverage on Cambrex in a research report on Tuesday, January 16th. They set an “outperform” rating for the company. Longbow Research cut Cambrex from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $60.00.
Cambrex (NYSE:CBM) last issued its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $1.27 EPS for the quarter, beating the consensus estimate of $1.10 by $0.17. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The firm had revenue of $182.28 million during the quarter, compared to analysts’ expectations of $181.39 million. During the same period in the prior year, the firm posted $1.23 earnings per share. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. equities research analysts anticipate that Cambrex will post 2.81 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CBM. Brown Advisory Inc. lifted its position in shares of Cambrex by 454.1% in the fourth quarter. Brown Advisory Inc. now owns 895,240 shares of the biotechnology company’s stock valued at $42,972,000 after buying an additional 733,663 shares during the last quarter. William Blair Investment Management LLC lifted its position in shares of Cambrex by 35.8% in the fourth quarter. William Blair Investment Management LLC now owns 2,353,032 shares of the biotechnology company’s stock valued at $112,946,000 after buying an additional 620,098 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Cambrex in the fourth quarter valued at approximately $22,203,000. Boston Partners lifted its position in shares of Cambrex by 118.5% in the fourth quarter. Boston Partners now owns 709,786 shares of the biotechnology company’s stock valued at $34,069,000 after buying an additional 384,897 shares during the last quarter. Finally, Peregrine Capital Management LLC acquired a new stake in shares of Cambrex in the fourth quarter valued at approximately $9,780,000.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.